REG - Polarean Imaging PLC - Block Listing Six Monthly Return

Polarean ImagingAnnouncement

26/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240126:nRSZ9598Aa&default-theme=true

RNS Number : 9598A  Polarean Imaging PLC  26 January 2024

Polarean Imaging Plc

("Polarean" or the "Company")

 
 
 

Block Listing Six Monthly Return

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in
advanced MRI scanning of the lungs, today makes the following notification
pursuant to Schedule Six of the AIM Rules for Companies regarding its existing
block admission arrangements:

 

 Name of applicant:                                                                     Polarean Imaging Plc
 Name of scheme:                                                                        Polarean Share Option Plan
 Number and class of securities originally admitted:                                    8,000,000 ordinary shares of £0.00037 each
 Date of admission:                                                                     29 July 2021
 Period of return:                                         From:                        27 July 2023     To:              26 January 2024
 Balance of unallotted securities under scheme(s) from previous return:                 3,172,835
 Plus: The amount by which the block scheme(s) has been increased since the             0
 date of the last return (if any increase has been applied for):

 Less: Number of securities issued/allotted under scheme(s) during period (see          1,948,262
 LR3.5.7G):

 Equals: Balance under scheme(s) not yet issued/allotted at end of period:              1,224,573
 Total number of securities in issue at the end of the period                           215,848,593

 Name of contact:              Charles F. Osborne, Jr., Chief Financial Officer
 Telephone number of contact:  + 44 (0)20 7933 8780 or polarean@walbrookpr.com

 

 

Enquiries:

 

 Polarean Imaging plc                                     www.polarean.com (http://www.polarean.com) / www.polarean-ir.com
                                                          (http://www.polarean-ir.com)
 Christopher von Jako, Chief Executive Officer            Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)                 +44 (0)20 7710 7600
 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment
 Banking)
 Nick Adams / Nick Harland (Corporate Broking)

 Walbrook PR        Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
                    (mailto:polarean@walbrookpr.com)
 Anna Dunphy /Phillip Marriage         Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082

 

About Polarean (www.polarean.com (http://www.polarean.com) )

The Company and its wholly-owned U.S. subsidiary, Polarean, Inc. are
revenue-generating, medical imaging technology companies. The Company aspires
to revolutionise pulmonary medicine by bringing the power and safety of MRI to
the respiratory healthcare community which is desperately in need of new
modern solutions to evaluate lung function. Polarean is dedicated to
researching, developing, and commercialising these novel imaging solutions
with their non-invasive and radiation-free functional MRI platform. The
Company strives to address the global unmet medical needs of more than 500
million patients worldwide suffering from chronic respiratory disease.
Polarean is a leader in the field of hyperpolarisation science and has
successfully developed the first and only hyperpolarised Xenon MRI contrast
agent (XENOVIEW™) to be FDA-approved in the United States. The Company also
commercialises the systems, software, and accessories to support fully
integrated modern respiratory imaging operations. Founded in 2012, with
offices in Durham, NC, and London, United Kingdom, Polarean is committed to
increasing global awareness of and broad access to its XENOVIEW MRI technology
platform. For the latest news and information about Polarean, please visit
www.polarean.com (http://www.polarean.com) .

 

PLC-RNS-2327

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRQKPBNPBKDFDB